Masimo delivered Q3 results that mostly aligned with guidance, yet it faces challenges in its non-healthcare segment.

Shares of Masimo Co. (NASDAQ:MASI – Get Free Report) have received an average rating of “Moderate Buy” from the seven ...

Fintel reports that on November 6, 2024, Raymond James upgraded their outlook for Masimo (NasdaqGS:MASI) from Market Perform ...

Masimo executives are back calling their consumer audio business Sound United, with a senior executive on a conference call ...

Needham analyst Michael Matson reiterated a Buy rating on Enovis (ENOV – Research Report) today and set a price target of $65.00. Michael ...

Masimo sells a range of devices used for patient monitoring that feature a proprietary pulse oximetry technology called Signal Extraction Technology (SET). In the latest update on that patent spat ...

Also, megacap technology stocks lost ground ... On the economic data front, all eyes are focused on the U.S. ISM Non-Manufacturing PMI, which is set to be released in a couple of hours. Economists, on ...

The dispute dates to 2013 when Apple sought Masimo’s technology to install pulse oximetry on its watch. Email correspondence ...

Masimo (Nasdaq:MASI) shares ticked up before hours today on third-quarter results that came in ahead of the consensus ...

Masimo Corp. ( (MASI) ) has released its Q3 earnings. Here is a breakdown of the information Masimo Corp. presented to its investors. Masimo ...

Revenue: US$504.6m (up 5.4% from 3Q 2023). Net income: US$9.80m (down 7.5% from 3Q 2023). Profit margin: 1.9% (down from 2.2% in 3Q 2023). The decrease in margin was driven by higher expenses. EPS ...

In its first earnings report since the departure of longtime CEO Joe Kiani, Masimo said Tuesday it is focused on reducing spending to drive long-term growth. The company continues to evaluate ...